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“Cardiac drugs in pregnancy” is a pocket-
sized book published by Springer as part
of their “Current Cardiovascular Therapy”
series. The book is a 130 page synop-
sis of cardiovascular therapy in the set-
ting of pregnancy, edited by two South
African cardiologists, Drs. Karen Sliwa
and John Anthony. There are six chap-
ters in the book, beginning with General
Principles and then proceeding through
a series of common cardiovascular prob-
lems such as hypertension, heart failure,
and arrhythmias written by a series of
experienced South African and European
cardiologists.
The title and topic seem unusual at first
glance—after all, how common is cardio-
vascular therapy in pregnancy? The editors
make the case—and this reviewer agrees
with them—that cardiovascular disease
is pregnancy is in fact relatively com-
mon, notably in the era of older and
older women having children, and that
cardiologists need an approach to these
problems. As well, some of the few well-
described human teratogens include drugs
commonly used by cardiologists, notably
the angiotensin-converting inhibitors and
warfarin. The book is an easy and enjoy-
able read, clearly written, and intended
for practicing clinicians. The editors and
chapter authors have focused on the
common and important rather than the
esoteric and arcane, which this reviewer
thoroughly agrees with. As an exam-
ple, fetal therapy is not discussed, being
beyond the scope of this book. The first
chapter deals with how the cardiovascular
system adapts during pregnancy and how
this may impact on therapy. Succeeding
chapters are disorder-specific. The authors
take care to ensure that their chapters pro-
vide not only a conceptual overview but
also recommendations to guide therapy.
The authors address what is confirmed by
the literature and, of equal importance,
areas where there is paucity of evidence
based medicine (or data) to guide ther-
apy decisions of cardiovascular disease in
pregnancy.
That being said, the book is not perfect
and one wonders if perhaps the inclu-
sion of one of small but active com-
munity of human teratogen investigators
or a consulting obstetrician as a chap-
ter author might have been useful. As
an example, the concept of baseline risk
and the importance of a fulsome dis-
cussion on baseline risk as part of the
evaluation and therapeutic planning for
pregnancy is understated, which is regret-
table given the clear and compelling evi-
dence as to the importance of this—and
the consequences of misinformation—in
the setting of pregnancy and drug ther-
apy. There is also a somewhat uncrit-
ical view of some important issues in
the care of the pregnant woman. As an
example, more than one chapter cites the
US Food and Drug Administration clas-
sification of drug teratogenicity in terms
of assessment of pregnancy risk without
a deeper discussion as to the very real
limitations—acknowledged by the FDA -
of this classification system in terms of
real world evidence. The chapter on car-
diovascular adjustments during pregnancy
is there but is somewhat light on some
issues such as drug transfer across the pla-
centa, which is an increasingly interesting
and complex area of study. An increas-
ing population of cardiac patients—adult
survivors of congenital cardiac disease—
is not covered in a separate chapter but
is dealt with piece-meal. It seems to this
reviewer that this is not the best way
to address the complex problems of a
new and growing population of cardiac
patients, and the addition of a chapter
on pregnancy in adult survivors of con-
genital cardiac disease would be a use-
ful addition to the next edition of this
book.
These reservations aside, the book does
bring together in a single small volume
a large amount of highly relevant and
practical material covering those condi-
tions and problems most likely to be
encountered by cardiologists and con-
sulting internists. The advantages and
limitations of current therapy are con-
cisely outlined and the recommenda-
tions provided will be very useful in
guiding therapy. The inclusion of a
final chapter on the use of obstetri-
cal drugs in the management of cardio-
vascular disease is both novel and very
interesting.
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In summary, this small volume is a use-
ful and practical book that would be a very
useful part of the library of cardiologists
as well as internists whose consulting prac-
tices include the care of pregnant women.
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